Israel - engelsk - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 150 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.

Israel - engelsk - Ministry of Health

novartis israel ltd - capmatinib as dihydrochloride monohydrate - film coated tablets - capmatinib as dihydrochloride monohydrate 200 mg - capmatinib - tabrecta is indicated for the treatment of adult patients with metastatic non-small cell lung cancer (nsclc) whose tumors have a mutation that leads to mesenchymal-epithelial transition (met) exon 14 skipping as detected by an approved test.

Israel - engelsk - Ministry of Health

novartis israel ltd - olopatadine as hydrochloride - eye drops - olopatadine as hydrochloride 1 mg/ml - olopatadine - olopatadine - for the temporary prevention of itching of the eye due to allergic conjunctivitis.

Israel - engelsk - Ministry of Health

novartis israel ltd - moxifloxacin as hydrochloride - ophthalmic solution - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

Israel - engelsk - Ministry of Health

novartis israel ltd - fentanyl - patches - fentanyl 16.8 mg/patch - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - engelsk - Ministry of Health

novartis israel ltd - fentanyl - patches - fentanyl 2.1 mg/patch - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - engelsk - Ministry of Health

novartis israel ltd - fentanyl - patches - fentanyl 4.2 mg/patch - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - engelsk - Ministry of Health

novartis israel ltd - fentanyl - patches - fentanyl 8.4 mg/patch - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - engelsk - Ministry of Health

novartis israel ltd - fentanyl - patches - fentanyl 12.6 mg/patch - fentanyl - management of chronic pain and intractable pain requiring opioid analgesia.fentadol should only be used in patients who are already receiving opioid therapy, who have demonstrated opioid tolerance.

Israel - engelsk - Ministry of Health

novartis israel ltd - dabrafenib as mesilate - hard capsule - dabrafenib as mesilate 50 mg - dabrafenib - dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a braf v600 mutation.non-small cell lung cancer (nsclc) :dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a braf v600 mutation.adjuvant treatment of melanoma :dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with stage iii melanoma with braf v600 mutation, following complete resection.braf v600e mutation-positive locally advanced or metastatic anaplastic thyroid cancertafinlar is indicated, in combination with trametinib, for the treatment of patients with locally advanced or metastatic anaplastic thyroid cancer (atc) with braf v600e mutation and with no satisfactory locoregional treatment optionsbraf v600e mutation-positive unresectable or metastatic solid tumorstafinlar is indicated, in combination with trametinib, for the treatment of adult and pediatric patients 6 years of age and older with unresectable or metastatic solid tumors with braf v600e mutation who have progressed following prior treatment and have no satisfactory alternative treatment options. limitations of use: dabrafenib is not indicated for treatment of patients with colorectal cancer because of known intrinsic resistance to braf inhibition. dabrafenib is indicated, in combination with trametinib, for the treatment of pediatric patients 6 year of age and older with low-grade glioma (lgg) with a braf v600e mutation who require systemic therapy